Novartis
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Novartis sits in the top decile of US sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count).
Novartis: 265 sponsored US clinical trials, none currently recruiting.
Novartis sponsors 265 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 248 completed. 176 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 11 trials.
Top-decile sponsor footprint
Novartis ranks in the top decile of sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
248 of 264 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
265 total, page 5 of 6
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
NCT00170937
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
NCT00138515
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
NCT00138554
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
NCT00230074
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
NCT00138619
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
NCT00138580
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
NCT00171678
Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance
NCT00150020
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
NCT00171535
Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
NCT00171691
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
NCT00138541
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
NCT00171093
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
NCT00129831
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
NCT00128245
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
NCT00232102
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
NCT00232037
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
NCT00219024
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
NCT00171626
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
NCT00170924
A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.
NCT00171366
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
NCT00117754
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
NCT00139555
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
NCT00129818
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
NCT00232089
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT00699166
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
NCT00171145
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
NCT00117377
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
NCT00409643
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)
NCT00475800
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
NCT00149851
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
NCT00171483
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
NCT00232024
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
NCT00241007
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
NCT00171028
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
NCT00104442
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
NCT00170950
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
NCT00366938
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
NCT00171418
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir
NCT00219310
One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension
NCT00409851
An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States
NCT00237263
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
NCT00056459
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
NCT00057265
A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
NCT00171041
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
NCT00171587
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
NCT00170755
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
NCT00385931
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
NCT00094146
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
NCT00407212
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 46 |
| Phase 3 | 126 |
| Phase 4 | 50 |
Therapeutic Areas
How the Novartis archive is shaped
265 indexed studies, none listed as recruiting (0% open); 248 completed (94%).
Phase mix: 176 late (III/IV) vs 69 early (I/II) (later-stage heavy).
Top condition: Hypertension (11 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Novartis: archived-pipeline peers nationwide
Peers matched on 265 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Novartis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 265 archived trials
- Abbott Medical Devices · 261 trials · 9% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
- Pennington Biomedical Research Center · 258 trials · 13% recruiting
- University of Texas at Austin · 257 trials · 23% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Novartis page
265 registered trials is a research-attention snapshot, not an endorsement of Novartis or any single study.
- None of Novartis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypertension is the condition Novartis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis pipeline card: 265 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.